JP6841819B2 - 制御され、遅延された活性成分の放出を有する製剤 - Google Patents

制御され、遅延された活性成分の放出を有する製剤 Download PDF

Info

Publication number
JP6841819B2
JP6841819B2 JP2018513528A JP2018513528A JP6841819B2 JP 6841819 B2 JP6841819 B2 JP 6841819B2 JP 2018513528 A JP2018513528 A JP 2018513528A JP 2018513528 A JP2018513528 A JP 2018513528A JP 6841819 B2 JP6841819 B2 JP 6841819B2
Authority
JP
Japan
Prior art keywords
active ingredient
release
composition
range
propranolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018513528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530538A (ja
JP2018530538A5 (https=
Inventor
バウアー，フィン
ヴェデル，トルステン
モデルモーグ，ギュンター
ビルク，グドルーン
オグニベーネ，ロベルト
ルブダ，ディーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2018530538A publication Critical patent/JP2018530538A/ja
Publication of JP2018530538A5 publication Critical patent/JP2018530538A5/ja
Application granted granted Critical
Publication of JP6841819B2 publication Critical patent/JP6841819B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018513528A 2015-09-14 2016-08-25 制御され、遅延された活性成分の放出を有する製剤 Expired - Fee Related JP6841819B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15185028.6 2015-09-14
EP15185028 2015-09-14
EP15189045.6 2015-10-09
EP15189045 2015-10-09
PCT/EP2016/001430 WO2017045742A1 (de) 2015-09-14 2016-08-25 Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung

Publications (3)

Publication Number Publication Date
JP2018530538A JP2018530538A (ja) 2018-10-18
JP2018530538A5 JP2018530538A5 (https=) 2020-12-10
JP6841819B2 true JP6841819B2 (ja) 2021-03-10

Family

ID=56855404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513528A Expired - Fee Related JP6841819B2 (ja) 2015-09-14 2016-08-25 制御され、遅延された活性成分の放出を有する製剤

Country Status (8)

Country Link
US (2) US10874615B2 (https=)
EP (1) EP3349733A1 (https=)
JP (1) JP6841819B2 (https=)
KR (1) KR20180052126A (https=)
CN (1) CN108024966A (https=)
AU (1) AU2016321659A1 (https=)
CA (1) CA2998422A1 (https=)
WO (1) WO2017045742A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160235709A1 (en) 2012-08-31 2016-08-18 Molecular product management LLC Limited release lingual thioctic acid delivery systems
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58502097A (ja) * 1981-12-18 1983-12-08 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド ポリビニルアルコ−ルおよびポリエチレングリコ−ルの拡張性格子
JPH02502720A (ja) * 1987-03-25 1990-08-30 イー・アイ・デユポン・デ・ニモアス・アンド・カンパニー 活性物質を錠剤にするためのビニルアルコールホモ重合体および共重合体の使用
US6495656B1 (en) * 1990-11-30 2002-12-17 Eastman Chemical Company Copolyesters and fibrous materials formed therefrom
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5838571A (en) * 1996-01-29 1998-11-17 Alza Corporation Tablet press monitoring and controlling method and apparatus
WO2002003965A1 (en) * 2000-07-06 2002-01-17 Delsys Pharmaceutical Corporation Method for formulating healthcare products with enhanced stability
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
WO2004050066A1 (en) * 2002-11-27 2004-06-17 The University Of Georgia Research Foundation, Inc. Microspheres and related processes and pharmaceutical compositions
US7241838B2 (en) * 2003-12-19 2007-07-10 Eastman Chemical Company Blends of aliphatic-aromatic copolyesters with ethylene-vinyl acetate copolymers
US7368503B2 (en) * 2003-12-22 2008-05-06 Eastman Chemical Company Compatibilized blends of biodegradable polymers with improved rheology
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
MY164765A (en) * 2007-10-10 2018-01-30 Avantor Performance Mat Llc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
ES2401912T3 (es) * 2008-09-17 2013-04-25 Siegfried Ltd. Granulado que contiene nicotina
CN102695501A (zh) * 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 碎裂水凝胶
JP2013241341A (ja) * 2012-05-17 2013-12-05 Nisshin Kasei Kk マトリックス製剤用基剤、及び該基剤を用いた徐放性製剤
GB201412413D0 (en) * 2014-07-11 2014-08-27 Revolymer Uk Ltd Encapsulated benefit agent particles
WO2016015814A1 (de) * 2014-07-30 2016-02-04 Merck Patent Gmbh Pulverförmige, direkt verpressbare polyvinlalkohol-typen

Also Published As

Publication number Publication date
CN108024966A (zh) 2018-05-11
US20200246270A1 (en) 2020-08-06
JP2018530538A (ja) 2018-10-18
AU2016321659A1 (en) 2018-05-10
US10874615B2 (en) 2020-12-29
KR20180052126A (ko) 2018-05-17
WO2017045742A1 (de) 2017-03-23
EP3349733A1 (de) 2018-07-25
CA2998422A1 (en) 2017-03-23
US20190038562A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
JP6706245B2 (ja) 微結晶性セルロースを含む直接圧縮可能な組成物
Abdelkader et al. Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation
DK3174530T3 (en) DIRECT COMPATIBLE POLYVINYL ALCOHOLS
AU2018203021A1 (en) Bromocriptine formulations
EP2895150A1 (en) Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
TWI418370B (zh) 溶出安定性製劑
US20180207101A1 (en) Pulverulent, directly compressible polyvinyl alcohol grades
JP6841819B2 (ja) 制御され、遅延された活性成分の放出を有する製剤
EP2077822B1 (en) Oxcarbazepine-containing oral formulation and a process to obtain the same
CN111000812B (zh) 一种拉考沙胺片的制备方法
JP6855459B2 (ja) 媒体に依存しない活性成分の放出を有する錠剤
JP2020510626A (ja) 延長した活性物質送達を有する錠剤を製造するための直接打錠可能なマトリックス
WO2012107090A1 (en) Granulated composition comprising tadalafil and a disintegrant
WO2017093890A1 (en) Clobazam tablet formulation and process for its preparation
US20240269079A1 (en) Melatonin formulation in solid dosage form
Al-Shammary et al. Formulation and Evaluation of Immediate-Release Oral Tablets Containing Magnesium Aluminum Silicate-Loaded Simvastatin
CN116782888A (zh) 药物组合物
HK40026299A (en) Bromocriptine formulations
HK40026299B (en) Bromocriptine formulations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200730

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210218

R150 Certificate of patent or registration of utility model

Ref document number: 6841819

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees